Verisilicon Microelectronics (Shanghai) Co., Ltd. (688521.SH) plans to introduce a restricted stock incentive plan in 2026.

17:33 09/08/2026

ChipGen Corporation (688521.SH) has disclosed the draft of its restricted stock incentive plan for 2026, proposing to grant no more than 5.148 million shares of restricted stock to the incentive recipients, which accounts for approximately 0.9789% of the company's total share capital at the time of the announcement of the draft plan. Among these, the initial grant will not exceed 4.1184 million shares, with the total number of incentive recipients for the initial grant not to exceed 831 individuals. The grant price (including reserved grants) is set at 112.56 yuan per share.

Verisilicon Microelectronics (Shanghai) Co., Ltd. (688521.SH) disclosed its 2026 Restricted Stock Incentive Plan (draft), which aims to grant up to 5.148 million shares of restricted stock to incentive recipients, accounting for approximately 0.9789% of the company's total equity at the time of the announcement of the draft incentive plan. Of this amount, the initial grant will not exceed 4.1184 million shares, with the total number of initial incentive recipients not exceeding 831 people, and the grant price (including reserved grants) set at 112.56 yuan per share.

Sohu.com Limited Sponsored ADR (SOHU.US) Q2 2026 total revenue was $136 million, a year-on-year increase of 7%.

Sealand: Air passenger transport is expected to stabilize and recover, and industry profitability may welcome improvement.

HK Stock Market Move | GENFLEET-B (02595) rose nearly 4% as GFH375 entered a Phase III clinical trial for the registration of monotherapy for non-small cell lung cancer in China.

Sohu.com Limited Sponsored ADR (SOHU.US) Q2 2026 total revenue was $136 million, a year-on-year increase of 7%.

Sealand: Air passenger transport is expected to stabilize and recover, and industry profitability may welcome improvement.

HK Stock Market Move | GENFLEET-B (02595) rose nearly 4% as GFH375 entered a Phase III clinical trial for the registration of monotherapy for non-small cell lung cancer in China.